Letrozole Combined With Gonadotropins (Gn) for Ovarian Stimulation Undergoing in Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) in Patients With Polycystic Ovary Syndrome (PCOS)
Letrozole Combined With Gonadotropins (Gn) for Ovarian Stimulation Undergoing in Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) in Patients With Polycystic Ovary Syndrome (PCOS)
The purpose of this study is to determine whether letrozole combined with gonadotropins are
 effective in the ovarian hyperstimulating for IVF/ICSI in patients with PCOS.
Polycystic ovarian syndrome (PCOS) occurs in 4% to 7% of all women of reproductive age and
 20% of women presenting with anovulatory infertility. A significant proportion of these women
 will ultimately need assisted reproductive techniques. Various protocols of ovarian
 stimulation such as step up protocol, coasting, GnRH antagonists et al have been proposed for
 optimizing IVF results in patients with PCOS. The results of these studies have shown it not
 to be satisfied. The preliminary studies have proven that Letrozole, a potent and highly
 specific nonsteroidal aromatase inhibitor, could successfully induce ovulation in women with
 polycystic ovary syndrome. In spite of only a little study research of letrozole in IVF/ICSI
 cycle, for poor ovarian responders, addition of letrozole improved ovarian response to FSH
 and reduced gonadotrophin dose required for COH without having a negative impact on pregnancy
 rates. These reports prompted us to hypothesize that adjunctive use of letrozole in COH
 protocol for patients with PCOS would minimize the gonadotrophin dose, and consequently the
 cost, and lower the risk of OHSS in a IVF/ICSI treatment cycle.
Inclusion Criteria:

 -  patients with PCOS